Lehi, Utah – July 3, 2023 – Xevant, a leading provider of healthcare analytics and technology solutions, is pleased to announce the appointment of Mark Lewandowski and Don DeGolyer as the newest members to join the board of directors. With their extensive experience and deep understanding of the healthcare industry, Lewandowski and DeGolyer will play instrumental roles in guiding Xevant’s strategic initiatives and driving innovation across the medical industry.
Mark Lewandowski brings over 27 years of invaluable expertise in the employee benefits industry. Throughout his career, he has made significant contributions to various organizations, demonstrating a strong track record of success. Lewandowski served as the Senior Vice President of Business Development at a pharmacy benefit management (PBM) company, which he led for several years. He also co-founded Interchange Rx, a PBM specializing in the hospice industry, and MedalistRx, a groundbreaking, transparent PBM in the employer-sponsored healthcare space. Mark also serves as Chair of the PBM Compliance and Oversight Authority of the Oklahoma Insurance Commission.
Don DeGolyer has established a remarkable career in the healthcare sector, marked by his ability to identify emerging market trends and drive transformative growth. Recognized for his inspirational leadership and passion for innovation, DeGolyer has consistently achieved exceptional results by aligning objectives and incentives among stakeholders. Previously, he served as a Senior Healthcare Advisor at Koch Investment, where he developed a tech-enabled growth equity investment strategy. Currently, DeGolyer is advising TrialSpark, a tech-enabled clinical research organization focused on advancing biopharmaceuticals. Prior to that, Don held executive and leadership roles at Endo Pharmaceuticals, Novartis, Pfizer, and Johnson & Johnson.
Brandon Newman, CEO of Xevant, expressed his enthusiasm regarding the new board members, stating, “We are thrilled to welcome Mark Lewandowski and Don DeGolyer to our board of directors. Their impressive backgrounds and extensive knowledge of the healthcare industry will be critical as we continue to drive innovation and deliver cutting-edge solutions to our clients. Their addition further strengthens our ability to revolutionize healthcare analytics and technology, empowering organizations to make data-driven decisions that enhance patient care and optimize outcomes.”
The appointments of Mark Lewandowski and Don DeGolyer to Xevant’s board of directors reflect the company’s commitment to assembling a diverse and experienced leadership team that will drive innovation and create sustainable growth.
Xevant’s revolutionary pharmacy benefits platform infuses real-time automation and alerts throughout the data analysis process, accelerating and simplifying the painstaking task of report building for PBMs, TPAs, Health Plans, Brokers, and Consultants. With Xevant, critical pharmacy analysis that took weeks, months, or more can now be done instantly. The results are optimized business processes, reduced operating costs, and improved patient outcomes. Xevant is recognized as one of Modern Healthcare’s Best Places to Work and America’s No. 1 Fastest Growing Private Software Company on the 2022 Inc. 5000 list.
Please see more at www.xevant.com